NEJM paper fills in details on ‘remarkable’ CAR-T result in autoimmune disease
BioPharma Dive
by Ben Fidler
5h ago
The full results spotlight cell therapy’s potential to treat lupus and other inflammatory conditions, but also the problems drug developers must solve first ..read more
Visit website
Vir, in midst of restructuring, loses its chief medical officer
BioPharma Dive
by Delilah Alvarado
7h ago
The departure of Phil Pang, who played a key role in developing Vir’s COVID-19 antibody, comes amid a broader company restructuring ..read more
Visit website
Bavarian Nordic terminates cancer vaccine work
BioPharma Dive
by Jonathan Gardner
7h ago
The Danish company scrapped a vaccine in Phase 1 testing and will exit oncology altogether, focusing instead on infectious disease research ..read more
Visit website
United Therapeutics, in unusual step, sues FDA over rival’s drug application
BioPharma Dive
by Kristin Jensen
7h ago
The biotech alleges the agency is letting rival Liquidia sidestep the rules by accepting an amendment to an application that’s involved in a patent dispute ..read more
Visit website
Behind the new kind of cell therapy that just won FDA approval
BioPharma Dive
by Kelly Bilodeau
7h ago
One expert views Amtagvi’s approval as a catalyst for further investment in TIL therapies, akin to how Kymriah’s 2017 clearance buoyed CAR-T treatment ..read more
Visit website
FDA puts hold on Rapt trials of drug for eczema, asthma
BioPharma Dive
by Delilah Alvarado
1d ago
Rapt reported one case of liver failure in a study participant who received the biotech’s drug, which is seen by analysts as a possible competitor to Dupixent ..read more
Visit website
AstraZeneca gets new Tagrisso OK as drug succeeds in another trial
BioPharma Dive
by Ned Pagliarulo
1d ago
The FDA approved the targeted therapy together with chemo for first-line metastatic lung cancer, while fresh trial results supported earlier use ..read more
Visit website
Rick Gonzalez, longtime AbbVie CEO, to step down in July
BioPharma Dive
by Jonathan Gardner
1d ago
The veteran executive, who guided AbbVie through its separation from Abbott Laboratories, will be succeeded by Chief Operating Officer Robert Michael.  ..read more
Visit website
Iovance, with approval of ‘TIL’ cell therapy, readies for complex launch
BioPharma Dive
by Ben Fidler
1d ago
The biotech set a price of roughly $515,000 per patient for its therapy Amtagvi, the first to be approved based on a decades-old technique of using tumor-infiltrating lymphocytes.  ..read more
Visit website
AbbVie’s Cerevel deal hits an uncommon roadblock
BioPharma Dive
by Jacob Bell
1d ago
A “second request” from the Federal Trade Commission could protract the timing of AbbVie’s proposed acquisition, which is slated to close around the middle of the year ..read more
Visit website

Follow BioPharma Dive on FeedSpot

Continue with Google
Continue with Apple
OR